The first author of the above article [Chao T-T, Wang C-Y, Lai C-C, Chen Y-:L, Tsai Y-T, Chen P-T, Lin H-I, Huang Y-CT, Shiau C-W, Yu C-J, and Chen K-F (2014) J Pharmacol Exp Ther 351(2):352-358. DOI: https://doi.org/10.1124/jpet.114.215418], recently identified the following errors:
In Figure 5 the authors misplaced (Fig 5A, left panel and Fig 5C, left panel) which appeared in another published article (Lung Cancer. 2014 ;85(2):152-60. doi: 10.1016/j.lungcan.2014.05.024).
The results of Figure 5 are consistent with the conclusions published in the original article.
The corrected figure appears below.
In Figure 6B the western of CIP2A, p-AKT, AKT and actin of nos. 1, 2, and 3 were similar to nos. 9, 8, and 7.
Effect of erlotinib or TD-19 on H460 xenograft tumor growth in nude mice. (A) Mice were treated with vehicle, erlotinib or TD-19 p.o at 10 mg/kg daily for 3 weeks. TD-19 inhibited tumor growth by approximately 80% (left). There was no difference in body weight (right). Data are shown as mean ± SD. n=6, *, P < 0.05; **, P < 0.01. Statistical analyzed by ANOVA. (B) Western blot analysis of CIP2A, p-AKT and AKT in H460 tumors. Ratio of CIP2A to actin is shown below each western blot data set. Immunoblots were quantitated using VisionWork LS software. †† Represents the p value < 0.01 when comparing the mean percentage of the TD19-treated group (no. 10,11,12) with the mean percentage of the vehicle group (no.7, 8 ,9) by ANOVA. (C) Analysis of PP2A activity in tumors. Data are shown as mean ± SD. n = 6; *, P < 0.05; **, P < 0.01. All data are representative of three independent experiments. Statistically analyzed by ANOVA. (D) Immunohistochemical stain and quantitative analyses of CIP2A, p-AKT and AKT in H460 xenografts tumors (400X magnification). Data are shown as mean ± SD. n = 6; *, P < 0.05. Statistical analyzed by ANOVA.
The results of Figure 6 are consistent with the conclusions published in the original article.
The corrected figure appears below.
- Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics
In this issue
Correction to “TD-19, an Erlotinib Derivative, Induces Epidermal Growth Factor Receptor Wild-Type Nonsmall-Cell Lung Cancer Apoptosis through CIP2A-Mediated Pathway”
